LRP8 and neoplasm: LRP8‐targeting strategies could include antibody approaches based on therapeutic monoclonal antibodies, for example, exploiting its role in tumor progression, or with antibody‐drug conjugates (ADC) to capitalize on its restricted pattern of expression.